These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19954252)

  • 1. Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles.
    Bonezzi K; Taraboletti G; Borsotti P; Bellina F; Rossi R; Giavazzi R
    J Med Chem; 2009 Dec; 52(23):7906-10. PubMed ID: 19954252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin.
    Bellina F; Cauteruccio S; Monti S; Rossi R
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5757-62. PubMed ID: 16950621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular disrupting agents.
    Lippert JW
    Bioorg Med Chem; 2007 Jan; 15(2):605-15. PubMed ID: 17070061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.
    Knox AJ; Price T; Pawlak M; Golfis G; Flood CT; Fayne D; Williams DC; Meegan MJ; Lloyd DG
    J Med Chem; 2009 Apr; 52(8):2177-80. PubMed ID: 19331414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular disrupting agents.
    Pilat MJ; Lorusso PM
    J Cell Biochem; 2006 Nov; 99(4):1021-39. PubMed ID: 16927308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1H-imidazoles.
    Wiglenda T; Gust R
    J Med Chem; 2007 Apr; 50(7):1475-84. PubMed ID: 17352461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.
    Simoni D; Romagnoli R; Baruchello R; Rondanin R; Grisolia G; Eleopra M; Rizzi M; Tolomeo M; Giannini G; Alloatti D; Castorina M; Marcellini M; Pisano C
    J Med Chem; 2008 Oct; 51(19):6211-5. PubMed ID: 18783207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
    Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of anti-microtubule biaryls and preliminary evaluation as vascular-disrupting agents.
    Joncour A; Liu JM; Décor A; Thoret S; Wdzieczak-Bakala J; Bignon J; Baudoin O
    ChemMedChem; 2008 Nov; 3(11):1731-9. PubMed ID: 18785200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of (3,4,5-trimethoxyphenyl)indol-3-ylmethane derivatives as potential antivascular agents.
    Dupeyre G; Chabot GG; Thoret S; Cachet X; Seguin J; Guénard D; Tillequin F; Scherman D; Koch M; Michel S
    Bioorg Med Chem; 2006 Jul; 14(13):4410-26. PubMed ID: 16529936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applying linear interaction energy method for binding affinity calculations of podophyllotoxin analogues with tubulin using continuum solvent model and prediction of cytotoxic activity.
    Alam MA; Naik PK
    J Mol Graph Model; 2009; 27(8):930-43. PubMed ID: 19286405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
    Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG
    Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system.
    Murugaiah AM; Wallinder C; Mahalingam AK; Wu X; Wan Y; Plouffe B; Botros M; Karlén A; Hallberg M; Gallo-Payet N; Alterman M
    Bioorg Med Chem; 2007 Nov; 15(22):7166-83. PubMed ID: 17825570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tubulin-binding dibenz[c,e]oxepines: Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents.
    Rossington SB; Hadfield JA; Shnyder SD; Wallace TW; Williams KJ
    Bioorg Med Chem; 2017 Mar; 25(5):1630-1642. PubMed ID: 28143677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, modelling, and antimitotic properties of tricyclic systems characterised by a 2-(5-Phenyl-1H-pyrrol-3-yl)-1,3,4-oxadiazole moiety.
    Pinna GA; Murineddu G; Murruzzu C; Zuco V; Zunino F; Cappelletti G; Artali R; Cignarella G; Solano L; Villa S
    ChemMedChem; 2009 Jun; 4(6):998-1009. PubMed ID: 19291736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The total synthesis and biological properties of the cytotoxic macrolide FD-891 and its non-natural (Z)-C12 isomer.
    García-Fortanet J; Murga J; Carda M; Marco JA; Matesanz R; Díaz JF; Barasoain I
    Chemistry; 2007; 13(18):5060-74. PubMed ID: 17516610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
    Zhu C; Hansen AR; Bateman T; Chen Z; Holt TG; Hubert JA; Karanam BV; Lee SJ; Pan J; Qian S; Reddy VB; Reitman ML; Strack AM; Tong V; Weingarth DT; Wolff MS; MacNeil DJ; Weber AE; Duffy JL; Edmondson SD
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4393-6. PubMed ID: 18614364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A direct and efficient total synthesis of the tubulin-binding agents ceratamine A and B; use of IBX for a remarkable heterocycle dehydrogenation.
    Coleman RS; Campbell EL; Carper DJ
    Org Lett; 2009 May; 11(10):2133-6. PubMed ID: 19385610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of conformationnally-restricted analogues of E7010 as inhibitors of tubulin assembly (ITA) and vascular disrupting agents (VDA).
    Prudhomme V; Cucca M; Nauton L; Andrieu E; Fereyrolles M; Lamoine S; Michelin C; Bennis K; Collin A; De Ceuninck F; Botez I; Mallet C; Ducki S
    Eur J Med Chem; 2022 Dec; 244():114809. PubMed ID: 36208509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides.
    Fassihi A; Azadpour Z; Delbari N; Saghaie L; Memarian HR; Sabet R; Alborzi A; Miri R; Pourabbas B; Mardaneh J; Mousavi P; Moeinifard B; Sadeghi-Aliabadi H
    Eur J Med Chem; 2009 Aug; 44(8):3253-8. PubMed ID: 19371979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.